Related Experiment Video
Updated: Apr 26, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
3.2K
[Possibilities using prolonged release dopamine receptor agonists in elderly and old age]
1Kafedra nevrologii GBOU "Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia", Moskva; Tsentr ékstrapiramidnykh zabolevaniĭ, Moskva.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|July 22, 2014
Summary
Dopamine receptor agonists can be safely used in elderly Parkinson's patients over 70. Careful patient selection and prolonged-release formulations minimize side effects, improving treatment options.
Area of Science:
- Neurology
- Pharmacology
Context:
- Parkinson's disease treatment has advanced with dopamine receptor agonists.
- Elderly patients (>70 years) often excluded due to side effect risks.
- High peak drug concentrations contribute to dopaminergic side effects.
Purpose:
- To evaluate the safety and efficacy of dopamine receptor agonists in elderly Parkinson's patients.
- To identify criteria for safe administration in older adults.
Summary:
- Prolonged-release formulations and careful patient selection enable safe use of dopamine receptor agonists in elderly patients.
- Clinical trials confirm comparable safety to middle-aged patients.
- Exclusion criteria include severe cognitive impairment, REM sleep disorder, orthostatic hypotension, falls, and decompensated somatic diseases.
Impact:
- Expands therapeutic options for elderly Parkinson's patients.
- Improves quality of life by managing motor symptoms safely in older populations.
- Highlights the importance of personalized medicine in geriatric neurology.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:15Drug Dosing: Geriatric Patients
392
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
392
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
365
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
365
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
377
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
377
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
849
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
849
01:26Oral Drug Delivery Systems: Continuous-Release Systems
297
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
297